Supplementary Figure 2.
Minor allele frequency analysis of BRCA1 and BRCA2 rare germline truncations. The scatter plot shows the relationship between MAFs of BRCA1 and BRCA2 germline truncation variants and site-specific P-values from LOH analysis. For both BRCA1 and BRCA2, the variants with low MAFs tend to display significant LOH. Selecting 0.05% cutoff for rare variants was based on balancing the inclusion of possible false-positives versus the loss of possible true-positives in subsequent burden test and LOH analysis. Correlation of truncation frequencies in 32 genes of interest between discovery set and validation set. Using the 3,125 and 1,627 cases in the discovery and validation cohorts, respectively, we used gene-specific tallies to calculate frequencies of truncations in the 32 genes found to be significant by burden testing. Figure shows the discovery and validation frequencies for each gene plotted on the abscissa and ordinate, respectively. These data were regressed using the ordinary least-squares (OLS) calculation. A Pearson's correlation coefficient of 0.6167 was found and the resulting regression line is also plotted (red). Boxplot shows the mutation rate distribution in basal cases with BRCA1/2 rare germline truncation (n=12) and basal cases without BRCA1/2 rare germline truncation variants (n=101, 2 cases missing somatic mutation information). Graph shows median central line, 50% confidence interval box and 95% confidence interval whiskers. P-value is calculated by Wilcoxon rank-sum test. WT  C61G  C64G  A1669S  T1685I  A1708V  P1859R  I1807M  H1421Y  T1376R  G1422E   81 82 83 84 85 86 87 88 89 90 91 92   BRCA1   Tubulin   pcDNA3   WT  L512V  A322P  T826K  F486L  I1044V  I1019V  N550H   pcDNA3   WT  I379M  K1476T  L246V  P1150S  A322P  L512V  D1546Y  M1783T   BRCA1   Tubulin   59   WT  pcDNA3  E23fs  D67Y  E85D  L668F  T826K  E1250*  E1415fs  A1708V  M1783T  R1835Q  L1844I   250 BRCA1 siRNA (3'UTR)
Supplementary Figure 5 . Western blot analysis of expression of BRCA1 mutant constructs. a) HDR assay results were tested for protein expression of the BRCA1 variant from the transfected plasmid. Cells that remained following flow cytometry analysis were extracted and soluble proteins analyzed by immunoblots. Since multiple experiments were done, each panel should be compared separately from the others. In all samples, the endogenous BRCA1 protein had been depleted by transfection of the siRNA targeting the 3'-UTR of the BRCA1 mRNA. All blots were probed for BRCA1, and strips show the proteins that migrated at about the 250 kDa marker, and strips were probed for a-tubulin, which migrated near the 50 kDa marker, as a loading control. pcDNA3  T1376R  H1421Y  G1422E  D1546Y  L1564P  V1247I  S1279P  pcDNA3   WT  A1669S  T1685I  A1708V  P1859R  I1807M  N1819S  P1579A   pcDNA3   WT  L668F  V772A  N1354T  P1637L  R1699W  Q1779fs  L1786P  G1788V  G1801D  pcDNA3   WT  A806T  R756S  E720K  S708Y  D695N  R612G  V1378I   pcDNA3   WT  I591T  L574P  T293S  R866C  D1152N  P1238L  Y179C   1 2 E1346K  E445Q  G462R  Y856H  E1219D  Q1281P  E962K   72 73 74 75 76 77 78 79 80   pcDNA3   WT  C61G  C64G  A1669S  T1685I  A1708V  P1859R  I1807M  H1421Y  T1376R  G1422E   81 82 83 84 85 86 87 88 89 90 91 92   BRCA1   Tubulin   pcDNA3   WT  L512V  A322P  T826K  F486L  I1044V  I1019V  N550H   pcDNA3   WT  I379M  K1476T  L246V  P1150S  A322P  L512V  D1546Y  M1783T   BRCA1   Tubulin   WT  pcDNA3  E23fs  D67Y  E85D  L668F  T826K  E1250*  E1415fs  A1708V  M1783T  R1835Q Figure 6 . Impact of C64G mutation in BRCA1 on splicing. Integrated genomic viewer screen capture of C64G mutation, leading to the activation of an infrequently used splice site, is shown. Two ovarian cases with C64G mutation and four ovarian cases without this mutation were shown. 
